• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Affectis Pharmaceuticals AG - Product Pipeline Review - H2 2011 Product Image

Affectis Pharmaceuticals AG - Product Pipeline Review - H2 2011

  • ID: 1964597
  • November 2011
  • 38 pages
  • Global Markets Direct

Affectis Pharmaceuticals AG – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Affectis Pharmaceuticals AG - Product Pipeline Review - H2 2011” provides data on the Affectis Pharmaceuticals AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Affectis Pharmaceuticals AG’s corporate website, SEC filings, investor presentations and featured press releases, both from Affectis Pharmaceuticals AG and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Affectis Pharmaceuticals AG - Brief Affectis Pharmaceuticals AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Affectis Pharmaceuticals AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage READ MORE >



List of Tables
List of Figures
Affectis Pharmaceuticals AG Snapshot
Affectis Pharmaceuticals AG Overview
Key Information
Key Facts
Affectis Pharmaceuticals AG – Research and Development Overview
Key Therapeutic Areas
Affectis Pharmaceuticals AG – Pipeline Review
Pipeline Products by Stage of Development
Affectis Pharmaceuticals AG – Pipeline Products Glance
Affectis Pharmaceuticals AG Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Affectis Pharmaceuticals AG–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Affectis Pharmaceuticals AG – Drug Profiles
AFC-08 mAb
Product Description
Mechanism of Action
R&D Progress
AFC-5128
Product Description
Mechanism of Action
R&D Progress
AFC-5261
Product Description
Mechanism of Action
R&D Progress
AFC-5278
Product Description
Mechanism of Action
R&D Progress
Cimicoxib
Product Description
Mechanism of Action
R&D Progress
EP-1 Receptor Antagonist Drug
Product Description
Mechanism of Action
R&D Progress
P2X4 Target
Product Description
Mechanism of Action
R&D Progress
Affectis Pharmaceuticals AG – Pipeline Analysis
Affectis Pharmaceuticals AG – Pipeline Products by Therapeutic Class
Affectis Pharmaceuticals AG - Pipeline Products By Target
Affectis Pharmaceuticals AG – Pipeline Products by Route of Administration
Affectis Pharmaceuticals AG – Pipeline Products by Molecule Type
Affectis Pharmaceuticals AG - Dormant Projects
Affectis Pharmaceuticals AG – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Affectis Pharmaceuticals AG, Deals Summary
Affectis Pharmaceuticals AG, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Affectis Pharmaceuticals Secures $4.47 Million In First Tranche Of Series D Financing Round
Affectis Pharmaceuticals Secures $15 million In Series C Financing Round
Affectis Pharmaceuticals Secures $5 Million In Series B Venture Financing Round
Partnerships
Affectis Pharmaceuticals Enters Into Drug Discovery Collaboration With Mitsubishi Tanabe
Affectis Pharmaceuticals Extends Co-Development Agreement With Mitsubishi Pharma
Neuronova Enters Into Co-Development Agreement With Evotec
Licensing Agreements
Affectis Pharmaceuticals Enters Into Licensing Agreement With Palau Pharma
Affectis Pharmaceuticals Enters Into Licensing Agreement With Merck Serono
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Affectis Pharmaceuticals AG – Pipeline by Therapy Area and Indication, H2 2011
Affectis Pharmaceuticals AG – Pipeline by Stage of Development, H2 2011
Affectis Pharmaceuticals AG - Phase II, H2 2011
Affectis Pharmaceuticals AG - Pipeline By Therapeutic Class, H2 2011
Affectis Pharmaceuticals AG - Pipeline By Target, H2 2011
Affectis Pharmaceuticals AG – Pipeline By Route of Administration, H2 2011
Affectis Pharmaceuticals AG – Pipeline By Molecule Type, H2 2011
Affectis Pharmaceuticals AG - Dormant Developmental Projects, 2010
Affectis Pharmaceuticals AG, Deals Summary
Affectis Pharmaceuticals Secures $4.47 Million In First Tranche Of Series D Financing Round
Affectis Pharmaceuticals Secures $15 million In Series C Financing Round
Affectis Pharmaceuticals Secures $5 Million In Series B Venture Financing Round
Affectis Pharmaceuticals Enters Into Drug Discovery Collaboration With Mitsubishi Tanabe
Affectis Pharmaceuticals Extends Co-Development Agreement With Mitsubishi Pharma
Neuronova Enters Into Co-Development Agreement With Evotec
Affectis Pharmaceuticals Enters Into Licensing Agreement With Palau Pharma
Affectis Pharmaceuticals Enters Into Licensing Agreement With Merck Serono

List of Figures
Affectis Pharmaceuticals AG – Pipeline by Therapy Area and Indication, H2 2011
Affectis Pharmaceuticals AG – Pipeline by Stage of Development, H2 2011
Affectis Pharmaceuticals AG – Pipeline By Therapeutic Class, H2 2011
Affectis Pharmaceuticals AG – Pipeline By Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos